Repligen (RGEN) Competitors $114.12 +0.59 (+0.52%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGEN vs. TECH, A, DHR, TMO, BIIB, UTHR, INCY, NBIX, BMRN, and EXELShould you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Bio-Techne (TECH), Agilent Technologies (A), Danaher (DHR), Thermo Fisher Scientific (TMO), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), and Exelixis (EXEL). These companies are all part of the "medical" sector. Repligen vs. Its Competitors Bio-Techne Agilent Technologies Danaher Thermo Fisher Scientific Biogen United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability. Is TECH or RGEN more profitable? Bio-Techne has a net margin of 6.02% compared to Repligen's net margin of -2.05%. Bio-Techne's return on equity of 13.43% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Bio-Techne6.02% 13.43% 10.32% Repligen -2.05%4.61%3.24% Which has more volatility and risk, TECH or RGEN? Bio-Techne has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Do analysts prefer TECH or RGEN? Bio-Techne currently has a consensus target price of $70.42, suggesting a potential upside of 37.20%. Repligen has a consensus target price of $166.67, suggesting a potential upside of 46.04%. Given Repligen's higher probable upside, analysts plainly believe Repligen is more favorable than Bio-Techne.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Techne 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.77Repligen 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has preferable earnings and valuation, TECH or RGEN? Bio-Techne has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-Techne$1.22B6.60$73.40M$0.46111.57Repligen$673.96M9.53-$25.51M-$0.25-456.50 Does the media favor TECH or RGEN? In the previous week, Bio-Techne had 2 more articles in the media than Repligen. MarketBeat recorded 18 mentions for Bio-Techne and 16 mentions for Repligen. Bio-Techne's average media sentiment score of 1.23 beat Repligen's score of 0.98 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 10 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in TECH or RGEN? 98.9% of Bio-Techne shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 3.9% of Bio-Techne shares are held by company insiders. Comparatively, 1.2% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryBio-Techne beats Repligen on 14 of the 16 factors compared between the two stocks. Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGEN vs. The Competition Export to ExcelMetricRepligenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.42B$3.10B$5.75B$10.27BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-456.6321.4675.2326.34Price / Sales9.53246.37458.6889.55Price / Cash36.5544.4425.8129.91Price / Book3.249.5913.246.27Net Income-$25.51M-$53.20M$3.29B$270.67M7 Day Performance-5.45%-0.02%0.69%2.71%1 Month Performance-8.22%3.82%4.50%5.87%1 Year Performance-18.48%8.98%73.37%25.85% Repligen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGENRepligen4.8447 of 5 stars$114.13+0.5%$166.67+46.0%-18.9%$6.42B$673.96M-456.631,778Positive NewsAnalyst ForecastAnalyst RevisionTECHBio-Techne4.993 of 5 stars$54.11-0.6%$70.42+30.1%-31.4%$8.53B$1.22B117.633,100Positive NewsAAgilent Technologies4.5788 of 5 stars$128.13-0.5%$139.25+8.7%-10.3%$36.50B$6.51B30.0817,900Analyst ForecastAnalyst RevisionDHRDanaher4.9923 of 5 stars$198.74-0.7%$246.35+24.0%-30.7%$143.36B$23.88B42.2963,000Positive NewsDividend AnnouncementTMOThermo Fisher Scientific4.9712 of 5 stars$487.11-1.1%$589.38+21.0%-21.5%$186.01B$42.88B28.17125,000Positive NewsBIIBBiogen4.6991 of 5 stars$141.35+0.5%$185.74+31.4%-26.0%$20.62B$9.68B13.517,605Positive NewsUTHRUnited Therapeutics4.8109 of 5 stars$394.62-1.5%$429.62+8.9%+19.4%$18.07B$2.88B15.401,305Positive NewsAnalyst RevisionINCYIncyte4.7434 of 5 stars$86.56-0.1%$82.53-4.7%+30.7%$16.92B$4.24B19.672,617Positive NewsAnalyst DowngradeShort Interest ↓NBIXNeurocrine Biosciences4.7758 of 5 stars$143.80-0.2%$160.00+11.3%+16.0%$14.29B$2.36B42.541,800Positive NewsBMRNBioMarin Pharmaceutical4.9768 of 5 stars$56.38-2.4%$92.04+63.3%-36.3%$11.09B$2.85B16.733,040Positive NewsAnalyst UpgradeShort Interest ↑EXELExelixis4.6977 of 5 stars$37.69-0.5%$44.06+16.9%+48.0%$10.20B$2.17B18.121,147Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies Bio-Techne Alternatives Agilent Technologies Alternatives Danaher Alternatives Thermo Fisher Scientific Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGEN) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGEN Stock Alerts